Search Results

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that the company’s therapeutic Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform and biologics will be featured in a poster at the 67th Biophysical Society Annual Meeting.

The American Cancer Society and the American Society of Clinical Oncology announced an expanded collaboration to make it simpler for patients to find authoritative cancer information online.

SimBioSys announced a strategic partnership that aims to significantly reduce oncology drug development times and cut development costs by using AI and biophysical modeling to better understand unique tumor spatial biophysical characteristics.

Cellens, Inc., an early-stage cancer diagnostic company pioneering in applying mechanobiology and machine learning analysis announced that it is collaborating with Bruker BioAFM, a business unit of Bruker, to develop the world’s first clinical diagnostic tests that leverage multi-parametric, single-cell biophysical markers and machine learning.

Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced that three abstracts have been accepted for presentation at the Endocrine Society’s ENDO 2024 Meeting to be held June 1-4, 2024, in Boston, Massachusetts.